Alcidion Group Ltd

Cyan C3G Fund continues to hold Alcidion (ALC) despite recent challenges, as the company has faced delays in securing new healthcare contracts in the UK, contributing to its price decline. The company confirmed over $35 million in contracted revenue for FY24, with a total of $125 million in contracted revenue, alongside a solid net cash position of $8 million. Given its current market capitalization of $70 million and expectations for a stronger second half, Cyan C3G Fund believes the recent price movement has been overly pessimistic. The Fund remains confident in Alcidion's long-term prospects, especially as it continues to leverage its established position in the healthcare sector.

Cyan C3G Fund continues to hold Alcidion (ALC) despite a 12% decline in share price. The company has faced challenges in winning investor confidence, partly due to delays in securing new contracts within the NHS system in the UK. As a result, Alcidion has reduced its cost base following a significant cash outflow in 1H24. While these developments have been frustrating, Cyan C3G Fund believes the company is well-positioned to secure new contracts in the next six months, particularly with its $200m tender pipeline. A recent $3.4m contract extension with the Dartford and Gravesham NHS Trust underscores the potential for future contract wins. The Fund maintains its position, anticipating a positive turnaround for the company.

Cyan C3G Fund continues to hold its position in Alcidion Group Ltd (ALC), a healthcare software provider that recently secured two significant contracts. The company was named the Preferred EPR Supplier to North Cumbria UK, a 10-year deal worth A$30-40m, marking a major milestone in its UK expansion. Additionally, Alcidion signed a 5-year, A$4m deal with Hume Rural Health in Victoria. These contracts are particularly appealing due to their high margins and recurring long-term revenues, with minimal additional staffing required for the North Cumbria project, ensuring a large portion of the revenues flow to the bottom line. Despite the recent rise in the stock price, the Fund believes there is further upside potential, particularly with the company’s robust $200m+ tender pipeline and strong cashflow generation. With these promising developments, Cyan C3G Fund expects continued contract wins and a significant runway for further price appreciation.

Cyan C3G Fund continues to hold its position in Alcidion Group Ltd (ALC) despite a recent 14% decline in share price. The company secured two significant contract wins, including a 10-year, A$30-40m deal with North Cumbria UK and a 5-year, A$4m deal with Hume Rural Health in Victoria. However, Cyan C3G Fund believes the market may be reacting to expectations of a seasonally weak Q1 cash flow report, which is set to be released at the end of October. The Fund remains confident that recent cost-cutting initiatives will lead to a materially improved cost base, positively impacting the company's financials in the coming months. With these strategic contracts and expected operational improvements, Cyan C3G Fund maintains its position in Alcidion.

Cyan C3G Fund continues to hold its position in Alcidion Group Ltd (ALC) following the announcement of two new contracts, worth $4.5m and $3.7m, with Northern Adelaide Local Health Network and Peninsula Health, respectively. These contracts further strengthen the company’s growing recurring revenue stream, which now totals $30m per annum. Despite the positive news flow, the stock's price has not risen as expected, which the Fund sees as an opportunity, given Alcidion’s modest market cap of ~$80m and its attractive EV/Sales ratio of 2.5x. With ongoing growth in the medical software sector, Cyan C3G Fund believes there is substantial upside potential for Alcidion moving forward.

Cyan C3G Fund continues to hold Alcidion Group Ltd. (ALC) following a strong quarterly update that revealed $13.1 million in new contract wins, surpassing the two major contract announcements of $4.5 million and $3.7 million previously disclosed. This performance highlights Alcidion’s ongoing success in securing significant business, particularly within the UK health system. The recent announcement of a $5-$7 million contract in Wales further validates Alcidion's growing presence in the UK market. Given the company’s strong contract pipeline and expanding footprint in key regions, Cyan C3G Fund remains optimistic about Alcidion's prospects.

Cyan C3G Fund continues to hold Alcidion Group Ltd. (ALC) due to the company’s strong performance and significant contract wins. Alcidion recently announced a major A$37.5m contract with the North Cumbria Hospital network in the UK, which will span 10 years, with $8-9m expected to be recognized in the current financial year. This contract is expected to drive ALC to an EBITDA and cash-flow positive result for FY25. In addition, the company secured its first contract in Wales valued at $5.5m, further bolstering its growth prospects. With $7.7m in cash as of December 2024 and a strong billing cycle, Alcidion is well-positioned to improve its cash position by 30 June 2025. Given these positive developments and the importance of the new contracts, Cyan C3G Fund remains optimistic about Alcidion’s future and continues to hold the stock.